Humacyte Stock Today
| HUMAW Stock | USD 0.51 0.04 8.51% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Humacyte is selling for under 0.51 as of the 28th of March 2025; that is 8.51 percent increase since the beginning of the trading day. The stock's lowest day price was 0.43. Humacyte has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of December 2024 and ending today, the 28th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 24th of November 2020 | Category Healthcare | Classification Health Care |
Humacyte is entity of United States. It is traded as Stock on NASDAQ exchange. More on Humacyte
Moving together with Humacyte Stock
Moving against Humacyte Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Humacyte Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Humacyte can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Humacyte's financial leverage. It provides some insight into what part of Humacyte's total assets is financed by creditors.
LiquidityHumacyte has accumulated 57.51 M in total debt. Note, when we think about Humacyte's use of debt, we should always consider it together with its cash and equity.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Humacyte (HUMAW) is traded on NASDAQ Exchange in USA. It is located in 2525 East North Carolina Highway 54, Durham, NC, United States, 27713 and employs 183 people. Humacyte is listed under Biotechnology category by Fama And French industry classification. The company classifies itself under Biotechnology sector and is part of Health Care industry.
Humacyte generates negative cash flow from operations
Check Humacyte Probability Of Bankruptcy
Humacyte Historical Income Statement
Humacyte Stock Against Markets
Humacyte Corporate Management
| Harold Alterson | Senior Quality | Profile | |
| MS MS | Chief Officer | Profile | |
| Sabrina Osborne | Executive People | Profile | |
| Kiernan MD | Chief Officer | Profile | |
| Dale Sander | Chief CFO | Profile | |
| William Scheessele | Chief Officer | Profile |
Additional Tools for Humacyte Stock Analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.